The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not a bad story imo..
By-Health currently expects to be in a position to complete the last of its eight studies and file its regulatory submission to the SAMR for Fruitflow in the first half of 2022, seeking to obtain a new permitted health function claim which would be in addition to the currently defined list of permitted health claims in China.
If By-Health is successful in obtaining a new permitted health function claim, it is currently expected that this would result in some significant orders for Fruitflow, potentially at a multiple of current total sales values. The Company continues to believe that Fruitflow has the potential to play an important role in the Chinese cardiovascular health market.
Hey pumpky, you cashing out here to go all in on hemo?
Fair enough. Good luck. But please don't post negative comments as it's only fair people do when there invested. To much of that in AIM already. ATB
Overall, those are pretty good results.
The increase in revenue from the AA is excellent, though tempered somewhat with a drop in sales in Q1 from this financial year, so, as Doc Horrible says, we may be flat or thereabouts in the current FY from the AA. That'll become a little clearer when the H1 numbers come out in a few months.
FF+ sales are still nothing to write home about in that it only made a contribution to cashflow of 40k (138.2 -49.1 - 48.7 ) though, to be fair, any effect of direct sales in China via the distributor will barely show in those numbers.
Another loss is anticipated by the board for the current FY, but it'll hopefully be of the same order, or less, than the year just reported on.
We have a bit of flesh on the By-Health calendar as to when they expect to submit on Blue-Hat. Realistically, I think you can add 6 to 18 months to that date before approval is granted, so the earliest we're likely to see that making an effect on our financials is late 2022, with 2023 being more realistic.
For the first time in recent years, the end of the current AA agreement we've talked about on here, has been formally mentioned ( well done Ian ) and we have a bit more detail. My expectation is that the agreement will be extended but on slightly different terms, which will hopefully be to our advantage. I'd expect, as Ford is negogiating with DSM, he'll also be looking at potential partnerships with others on the manufacturing side ( By-Health is the obvious candidate ) so we have both a backup plan, and also some leverage with DSM.
With a current market cap of 18 million, I don't expect DSM or By-Health to make an offer for us.
I'll hold what I've got, but don't feel a burning desire to buy any more. Mind you, the share price is above my last two sales so wtfdik
Had enough and sold;Good luck all
The key question for me is whether or not there has been any SAMR submission to date. Were the 2019 submissions dropped in favour of the new health claim submission? If so, then they will submit the new health claim submission in 2022 and it could be 2025/26 before it is approved. Alternatively if the original submissions went ahead in 2019, we could get an approval in 2022.
The revenue growth was actually in previous years, but skewed by Covid. Next year, we’ll probably be flat or a fall due to Covid.
Very appropriate user name for a holder of this share!
Loss reduced by 30% means to me 2 more years of losses to come . I expect IF will want a pay rise on the back of this light at the end of the tunnel FR's statement , how long is the tunnel ?
The patent was flogged to us for peanuts 11 mill shares are ATM worth not a lot. It might hold promise though which is what as kept this Ian Ford charity going .
I have been in PXS 12 years , to me it sounds like jam tomorrow which is what we always get --
'Potential sales volumes'
'fixed at favourable market conditions, '
Potential sales will depend on what they spend on advertising , the DSM % to PXS is secret so 'favourable' means not a lot.
It is really good to be given a much more detailed insight into the current Patents that are in operation, together with a synopsis of the activity in securing new Patents over the last 12 Months. Two if the "Patent Family" are even granted in China (which was always a concern of mine).
It is my belief that the value of the Company lies entirely in the nature of the Patents that are held.
Indeed, if you strip out the R&D costs from the Accounts (which presumably represents, in the main, the cost of securing the new patents) you could even go so far as to say that Provexis is now Operating In Profit.
It is good to see some sort of timescale attributed to the SAMR approval process even if that timescale is longer than we hoped.
Downside risk of slight concern is the renegotiation of the DSM Agreement - that could go either way.
It does look as if things are progressing in China but I can't see any approval being achieved until late 2022 and it's anyone's guess as to when any revenues will be produced so very much on the back burner in that respect. The new agreement with DSM is to be shrouded in secrecy same as the 2010 agreement so shareholders won't know the details anyway! After 11 years and having been the "jewel in DSM's crown" the contract still only provides £500k of income. Much cut & paste about interest from industry etc which never happens in reality. More fund raising needed so that hasn't been put to bed yet so more uncertainty. Directors emoluments slightly less than last year but still nearly £300k from a loss making business! Same old, same old and the market has reacted with resigned indifference as expected. Bottom drawer for at least 2 years IMO.
i like the theme and end markets. well funded. taking an initial long position.
8 months, try 8 yrs +
I like this update
Jan2021
The Company continues to work on a potential Fruitflow+ nitrates product which would be supported by the Company's strong patent position in this area, with the involvement now of third party manufacturers and with some interest already generated from brand owners. The product will have anti-inflammatory and circulation benefits for athletes seeking to recover after exercise, properties which would also be potentially beneficial to a wide range of other consumers to include people who are less active and people who suffering from the symptoms of basic ageing.
Sept 2021 Update
The Company continues to work on a potential Fruitflow+ nitrates product which would be supported by the Company's strong patent position in this area. The product would have anti-inflammatory and circulation benefits for athletes seeking to recover after exercise, properties which would also be potentially beneficial to a wide range of other consumers to include people who are less active and people who suffering from the symptoms of basic ageing. In collaboration with DSM a trial batch of Fruitflow+ nitrates development products was manufactured during the year and sold to DSM.
Roll on 2022 then;A group Low loss of £225k, over 12 years in the making and still cannot "turn a profit"
Talks with DSM, who knows where that will end ? All good as far as I can see .
I will continue to add as and when I can. Wonder how the markets will react
Best results so far. As we thought bi-Heath is going for an extra unit/Heath claim. So first half 2022 is submission date. Revenues up 45% though we are still at a loss. I am sure IF will get a good new deal with DSM
It will be nice to get anything after 8 months
RNS's from PXS are like London buses........
Think with such a significant report being issued it warrants an rns from the company. You never know we might even improve sales.
No, the purpose of this RNS is to provide the preliminary results. Any significant information other than the results would likely be in a separate RNS.
By leaving any kind of rns until the last moment, states that it would not be any significant new information ,same old story
It's an important point, patents are crucial, and it seems that more studies produce further areas to be patented.
Yes agree. We have been getting loads of patents done over the last 2 years. All these will help in the eventual buy out